The pharmaceutical company Moberg Derma recently secured SEK 35 million in a new share issue. Both existing and new shareholders subscribed for shares in the issue. More than SEK 100 million has now been raised for its operations since the company was established in March 2006.
“We are very pleased with the interest shown by investors what has been a difficult market climate in recently. The new share issue has secured additional capital for the continued development and start of commercialization of the product portfolio, and has also strengthened the company’s shareholder group,” says Peter Wolpert, President and CEO of Moberg Derma.
Moberg Derma is developing a portfolio of medical products for skin disorders based on the company’s patented Kaprolac® principle, acquired projects and technology licensed from leading drug delivery companies. This spring the company announced its first commercial agreement for K101 for the treatment of nail fungus, after having reported positive phase III results. Moberg Derma intends to expand its existing product portfolio through in-house development as well as through further acquisitions.
Contact Moberg Derma
Peter Wolpert, President and CEO
Telephone: +46 8 - 522 307 00
Mobile: +46 70 - 735 71 35
E-mail: peter.wolpert@mobergderma.se
About Moberg Derma
Moberg Derma AB, Stockholm, Sweden, develops and commercializes patented medical products for the treatment of skin disorders. The company focuses on innovative products based on proven compounds. Moberg Derma outlicenses product rights to partners and distributors while maintaining certain promotion rights for the Nordic region. The company began operations at the Karolinska Institute in 2006 and currently has 10 employees. The principal owners are Östersjöstiftelsen (the Baltic Sea Foundation), private investors and management. For further information, please visit: www.mobergderma.se
“We are very pleased with the interest shown by investors what has been a difficult market climate in recently. The new share issue has secured additional capital for the continued development and start of commercialization of the product portfolio, and has also strengthened the company’s shareholder group,” says Peter Wolpert, President and CEO of Moberg Derma.
Moberg Derma is developing a portfolio of medical products for skin disorders based on the company’s patented Kaprolac® principle, acquired projects and technology licensed from leading drug delivery companies. This spring the company announced its first commercial agreement for K101 for the treatment of nail fungus, after having reported positive phase III results. Moberg Derma intends to expand its existing product portfolio through in-house development as well as through further acquisitions.
Contact Moberg Derma
Peter Wolpert, President and CEO
Telephone: +46 8 - 522 307 00
Mobile: +46 70 - 735 71 35
E-mail: peter.wolpert@mobergderma.se
About Moberg Derma
Moberg Derma AB, Stockholm, Sweden, develops and commercializes patented medical products for the treatment of skin disorders. The company focuses on innovative products based on proven compounds. Moberg Derma outlicenses product rights to partners and distributors while maintaining certain promotion rights for the Nordic region. The company began operations at the Karolinska Institute in 2006 and currently has 10 employees. The principal owners are Östersjöstiftelsen (the Baltic Sea Foundation), private investors and management. For further information, please visit: www.mobergderma.se
